Healthcare · NSE: SYNGENE
Syngene International
Q2 FY27 · From the investor presentation
- M.Cap
- ₹18,076Cr
- P/E
- 97.1×
- 1Y return
- −32.55%
- From 52W high
- −34.0%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 833 | 911 | -8.6% | 736 | +13.1% |
| EBITDA | 147 | 200 | -26.1% | 91 | +62.3% |
| EBITDA margin | 17.7% | 21.9% | -421 bps | 12.3% | +536 bps |
| One-off items | -7 | — | — | -13 | — |
| PBTProfit before tax | 47 | 85 | -44.8% | -19 | — |
| Net profit | 32 | 67 | -52.0% | -9 | — |
| EPS (₹) | 0.80 | 1.67 | -52.1% | -0.22 | — |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q2 FY26 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.
In short
- 01Q2 FY27 revenue from operations was Rs 833 Cr, up 13% quarter on quarter and down 9% year on year.
- 02Q2 operating EBITDA margin was 18%, reflecting lower revenues and forex hedge losses; about mid-20s excluding the hedge loss.
- 03PAT before exceptional items was Rs 38 Cr in Q2 FY27 versus Rs 67 Cr a year earlier.
- 04Syngene signed the first manufacturing agreement for its Bayview biologics facility with a large pharma customer.
- 05Process development for the Bayview contract starts in India this year, with drug-substance manufacturing at Bayview next year.
- 06Manpower cost optimisation is complete; other cost initiatives continue with benefits expected over coming quarters.
- 07Net cash stood at Rs 1,392 Cr as on 30 September 2026.
Capacity
Clinical Translational Sciences laboratory commissioned in Bengaluru
Slides · p. 6
Clinical Translational Sciences laboratory commissioned in Bengaluru
“Capability Enhancement: Commissioned a Clinical Translational Sciences laboratory in”
Segments
Bayview Biologics Facility: First manufacturing agreement signed for Bayview biologics facility
Slides · p. 6
Bayview Biologics Facility: First manufacturing agreement signed for Bayview biologics facility
“Bayview Biologics Facility: Syngene signed first manufacturing agreement for the Bayview”
Bayview Biologics Facility: Process development for Bayview contract to begin in India this year
Slides · p. 6
Bayview Biologics Facility: Process development for Bayview contract to begin in India this year
“Process development is scheduled to begin in India this year, followed”
Biologics Manufacturing: Additional biologics manufacturing contracts secured
Slides · p. 6
Biologics Manufacturing: Additional biologics manufacturing contracts secured
“Biologics Manufacturing: Secured additional manufacturing contracts, including an agreement”
Bayview Biologics Facility: Drug-substance manufacturing for Bayview contract to follow at Bayview next year
Slides · p. 6
Bayview Biologics Facility: Drug-substance manufacturing for Bayview contract to follow at Bayview next year
“by drug-substance manufacturing at Bayview next year, strengthening Syngene’s integrated”
Demand
16 of top 20 pharma companies are clients
Slides · p. 11
16 of top 20 pharma companies are clients
“talented scientists 16 out of top 20 pharma companies are clients”
Margins and costs
Q2 operating EBITDA margin would be in mid-20s excluding forex hedge loss
Slides · p. 6
Q2 operating EBITDA margin would be in mid-20s excluding forex hedge loss
“Adjusted for the forex hedge loss, the operating EBITDA margin for the quarter would be in the mid-20s range.”
Manpower optimisation completed; other cost initiatives underway with benefits expected
Slides · p. 6
Manpower optimisation completed; other cost initiatives underway with benefits expected
“completed, while other initiatives remain underway, with benefits expected over the coming”
Net forex loss Rs 61 Cr in Q2 FY27 versus Rs 12 Cr a year earlier
Slides · p. 27
Net forex loss Rs 61 Cr in Q2 FY27 versus Rs 12 Cr a year earlier
“Foreign exchange (gain)/loss, net 61 50 12 23% 421%”
Q2 FY27 operating EBITDA Rs 147 Cr, up 63% QoQ and down 26% YoY
Slides · p. 27
Q2 FY27 operating EBITDA Rs 147 Cr, up 63% QoQ and down 26% YoY
“Operating EBITDA (ex-other income) 147 91 200 63% -26%”
Q2 FY27 EBITDA Rs 175 Cr, down 18% YoY
Slides · p. 27
Q2 FY27 EBITDA Rs 175 Cr, down 18% YoY
“EBITDA 175 116 215 51% -18%”
Debt and working capital
Net cash of Rs 1,392 Cr as on 30 September 2026
Slides · p. 27
Net cash of Rs 1,392 Cr as on 30 September 2026
“Net cash/(debt) 1,392”
Management
Integrated Drug Discovery: Chemistry, Biology and Biotherapeutics brought under unified leadership of Chief Scientific Officer
Slides · p. 6
Integrated Drug Discovery: Chemistry, Biology and Biotherapeutics brought under unified leadership of Chief Scientific Officer
“by bringing Chemistry, Biology and Biotherapeutics under unified leadership of Chief Scientific”
One-offs
Exceptional employee termination benefits: Rs 6 Cr in Q2 FY27, Rs 10 Cr in Q1 FY27, net of tax
Slides · p. 27
Exceptional employee termination benefits: Rs 6 Cr in Q2 FY27, Rs 10 Cr in Q1 FY27, net of tax
“Excludes expenses recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy: Rs 6 Cr (net of tax) in Q2 FY27 and Rs 10 Cr (net of tax) in Q1 FY27”
Exceptional employee termination benefits Rs 16 Cr net of tax in H1 FY27
Slides · p. 6
Exceptional employee termination benefits Rs 16 Cr net of tax in H1 FY27
“Cr for Q2 FY27 and Rs 16 Cr for H1 FY27”
FY26 PAT excludes Rs 38 Cr gratuity liability increase from new labour codes
Slides · p. 28
FY26 PAT excludes Rs 38 Cr gratuity liability increase from new labour codes
“Excludes (i) impact of Rs. 38 Cr. (net of tax) pertaining to the net increase in gratuity liabilities on account of newly implemented labour codes”
Other
Q2 FY27 revenue from operations Rs 833 Cr, up 13% QoQ and down 9% YoY
Slides · p. 27
Q2 FY27 revenue from operations Rs 833 Cr, up 13% QoQ and down 9% YoY
“Revenue from operations 833 736 911 13% -9%”
H1 FY27 revenue from operations Rs 1,569 Cr, down 12% YoY
Slides · p. 6
H1 FY27 revenue from operations Rs 1,569 Cr, down 12% YoY
“Revenue from Rs 833 Cr Rs 1,569 Cr Operations +13% Q-o-Q -12% Y-o-Y”
PAT before exceptional items Rs 38 Cr in Q2 FY27, down 44% YoY
Slides · p. 27
PAT before exceptional items Rs 38 Cr in Q2 FY27, down 44% YoY
“PAT before exceptional items 38 1 67 37x -44%”
PAT after exceptional items Rs 32 Cr in Q2 FY27, down 52% YoY
Slides · p. 27
PAT after exceptional items Rs 32 Cr in Q2 FY27, down 52% YoY
“PAT after exceptional items 32 -9 67 n/m -52%”
Digital capabilities expanded through ChemVoyager and automated analytical systems
Slides · p. 6
Digital capabilities expanded through ChemVoyager and automated analytical systems
“capabilities through ChemVoyager, automated analytical systems and end-to-end sample”
Sources
- Investor presentation, Q2 FY27 Filed 27 Oct 2026 · 32 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.